Tech Company Financing Transactions
HI-Bio Funding Round
On 11/1/2022, HI-Bio secured $120 million in funding from Arch Venture Partners, Jeito Capital and Monograph Capital.
Transaction Overview
Company Name
Announced On
11/1/2022
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Undisclosed
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2 Tower Place 16th Floor South
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
HI-Bio� was founded on the idea that therapies for immune-mediated diseases (IMDs) have the potential to achieve better results for patients. Many IMDs stem from the dysfunction of cells that make up the immune system, including plasma cells, neutrophils, mast cells and more. These cells are responsible for critical functions and processes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Travis Murdoch
Vice President
Donna Flesher
Vice President
Houston Gilbert
Vice President
Gijsbert Grotenbreg
Vice President
Lara Mangravite
VP - Bus. Development
Carl Enell
VP - Bus. Development
Ariella Kelman
VP - Finance
Joyce Liaw
VP - General Counsel
Christina Carlson
VP - Operations
Lorna Dean
Browse more venture capital transactions:
Prev: 11/1/2022: Decentro venture capital transaction
Next: 11/1/2022: Qwick venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs